Environmental exposures, tumor heterogeneity, and colorectal cancer outcomes

Steven Agle, Prejesh Philips, Robert C G Martin

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

Considerable progress has been made in colorectal cancer (CRC) over the past two decades but it still remains the third commonest and third most deadly cancer in the USA. Epidemiologic and experimental studies have continued to describe links between environmental risk factors for developing nonhereditary CRC. However, the most significant recent advances have come through the understanding of CRC tumor heterogeneity and its impact on the variability of treatment efficacy. Using the KRAS mutation as a predictive biomarker for anti-epidermal growth factor receptor therapy is an example of how the genetic diversity of tumors can lead to a more individual or so-called personalized medicine with the goal of providing more benefits to patients, without unnecessary adverse side effects. Most recent reviews on this topic have focused on the key cancer pathways for which targeted therapies for CRC already exist. Less attention has recently been given to the three major genetic subtypes of CRC. Chromosomal instability, microsatellite instability, and CpG island methylator phenotype are thought to be the three major genetic and epigenetic alterations that drive tumorigenesis. In the past, these genetic alterations were used as a prognostic indicator, but recent data have demonstrated their correlation with treatment response.

Original languageEnglish (US)
Pages (from-to)189-194
Number of pages6
JournalCurrent Colorectal Cancer Reports
Volume10
Issue number2
DOIs
StatePublished - 2014
Externally publishedYes

Fingerprint

Environmental Exposure
Colorectal Neoplasms
Neoplasms
Chromosomal Instability
Microsatellite Instability
Precision Medicine
CpG Islands
Epidermal Growth Factor Receptor
Epigenomics
Epidemiologic Studies
Carcinogenesis
Therapeutics
Biomarkers
Phenotype
Mutation

Keywords

  • Colonic neoplasms
  • Colorectal cancer
  • Environmental exposure
  • Outcome assessment
  • Tumor heterogeneity

ASJC Scopus subject areas

  • Oncology
  • Gastroenterology
  • Hepatology

Cite this

Environmental exposures, tumor heterogeneity, and colorectal cancer outcomes. / Agle, Steven; Philips, Prejesh; Martin, Robert C G.

In: Current Colorectal Cancer Reports, Vol. 10, No. 2, 2014, p. 189-194.

Research output: Contribution to journalArticle

Agle, Steven ; Philips, Prejesh ; Martin, Robert C G. / Environmental exposures, tumor heterogeneity, and colorectal cancer outcomes. In: Current Colorectal Cancer Reports. 2014 ; Vol. 10, No. 2. pp. 189-194.
@article{77a99bce0a3f459fae8de7eec43203c6,
title = "Environmental exposures, tumor heterogeneity, and colorectal cancer outcomes",
abstract = "Considerable progress has been made in colorectal cancer (CRC) over the past two decades but it still remains the third commonest and third most deadly cancer in the USA. Epidemiologic and experimental studies have continued to describe links between environmental risk factors for developing nonhereditary CRC. However, the most significant recent advances have come through the understanding of CRC tumor heterogeneity and its impact on the variability of treatment efficacy. Using the KRAS mutation as a predictive biomarker for anti-epidermal growth factor receptor therapy is an example of how the genetic diversity of tumors can lead to a more individual or so-called personalized medicine with the goal of providing more benefits to patients, without unnecessary adverse side effects. Most recent reviews on this topic have focused on the key cancer pathways for which targeted therapies for CRC already exist. Less attention has recently been given to the three major genetic subtypes of CRC. Chromosomal instability, microsatellite instability, and CpG island methylator phenotype are thought to be the three major genetic and epigenetic alterations that drive tumorigenesis. In the past, these genetic alterations were used as a prognostic indicator, but recent data have demonstrated their correlation with treatment response.",
keywords = "Colonic neoplasms, Colorectal cancer, Environmental exposure, Outcome assessment, Tumor heterogeneity",
author = "Steven Agle and Prejesh Philips and Martin, {Robert C G}",
year = "2014",
doi = "10.1007/s11888-014-0221-x",
language = "English (US)",
volume = "10",
pages = "189--194",
journal = "Current Colorectal Cancer Reports",
issn = "1556-3790",
publisher = "Springer Science + Business Media",
number = "2",

}

TY - JOUR

T1 - Environmental exposures, tumor heterogeneity, and colorectal cancer outcomes

AU - Agle, Steven

AU - Philips, Prejesh

AU - Martin, Robert C G

PY - 2014

Y1 - 2014

N2 - Considerable progress has been made in colorectal cancer (CRC) over the past two decades but it still remains the third commonest and third most deadly cancer in the USA. Epidemiologic and experimental studies have continued to describe links between environmental risk factors for developing nonhereditary CRC. However, the most significant recent advances have come through the understanding of CRC tumor heterogeneity and its impact on the variability of treatment efficacy. Using the KRAS mutation as a predictive biomarker for anti-epidermal growth factor receptor therapy is an example of how the genetic diversity of tumors can lead to a more individual or so-called personalized medicine with the goal of providing more benefits to patients, without unnecessary adverse side effects. Most recent reviews on this topic have focused on the key cancer pathways for which targeted therapies for CRC already exist. Less attention has recently been given to the three major genetic subtypes of CRC. Chromosomal instability, microsatellite instability, and CpG island methylator phenotype are thought to be the three major genetic and epigenetic alterations that drive tumorigenesis. In the past, these genetic alterations were used as a prognostic indicator, but recent data have demonstrated their correlation with treatment response.

AB - Considerable progress has been made in colorectal cancer (CRC) over the past two decades but it still remains the third commonest and third most deadly cancer in the USA. Epidemiologic and experimental studies have continued to describe links between environmental risk factors for developing nonhereditary CRC. However, the most significant recent advances have come through the understanding of CRC tumor heterogeneity and its impact on the variability of treatment efficacy. Using the KRAS mutation as a predictive biomarker for anti-epidermal growth factor receptor therapy is an example of how the genetic diversity of tumors can lead to a more individual or so-called personalized medicine with the goal of providing more benefits to patients, without unnecessary adverse side effects. Most recent reviews on this topic have focused on the key cancer pathways for which targeted therapies for CRC already exist. Less attention has recently been given to the three major genetic subtypes of CRC. Chromosomal instability, microsatellite instability, and CpG island methylator phenotype are thought to be the three major genetic and epigenetic alterations that drive tumorigenesis. In the past, these genetic alterations were used as a prognostic indicator, but recent data have demonstrated their correlation with treatment response.

KW - Colonic neoplasms

KW - Colorectal cancer

KW - Environmental exposure

KW - Outcome assessment

KW - Tumor heterogeneity

UR - http://www.scopus.com/inward/record.url?scp=84903705354&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84903705354&partnerID=8YFLogxK

U2 - 10.1007/s11888-014-0221-x

DO - 10.1007/s11888-014-0221-x

M3 - Article

VL - 10

SP - 189

EP - 194

JO - Current Colorectal Cancer Reports

JF - Current Colorectal Cancer Reports

SN - 1556-3790

IS - 2

ER -